Trials / Withdrawn
WithdrawnNCT07111013
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
A 12-Month, Multicenter, Open-Label Extension (OLE) Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lifitegrast/perfluorohexyloctane (PFHO) | fixed-dose combination (FDC) (5%/95%) |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2025-08-08
- Last updated
- 2025-12-10
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07111013. Inclusion in this directory is not an endorsement.